Clindamycin - Felixvet

Kansas City, Mo. — July 7, 2026 — Felixvet Inc. today announced the addition of Clindamycin Hydrochloride Tablets to its growing product portfolio. The product received approval from the U.S. Food and Drug Administration (FDA) on June 27, 2025 and is indicated for the treatment of skin infections, wounds and abscesses, dental infections, and osteomyelitis in dogs caused by susceptible bacterial organisms.

“Veterinarians manage bacterial infections every day, and they need treatment options they can trust and prescribe with confidence,” said Lauren Landolph, Vice President, Commercial Strategy & Distribution Channels at Felixvet. “The addition of Clindamycin Hydrochloride Tablets expands access to an important antimicrobial while supporting the practical needs of veterinary teams and pet owners.”

Product Details

Three white plastic bottles of Clindamycin Hydrochloride Tablets for dogs, lined up side-by-side to showcase three different strengths: 150 mg, 75 mg and 25 mg. — *Available in 25 mg, 75 mg and 150 mg strengths.*

Clindamycin Hydrochloride Tablets provide veterinarians with an FDA-approved, bioequivalent option for the treatment of select bacterial infections in dogs, including skin infections, deep wounds and abscesses, dental infections, and osteomyelitis.

Available configurations include:

25 mg tablets – 400-count bottles
75 mg tablets – 200-count bottles
150 mg tablets – 100-count bottles

Each tablet is scored to support accurate dosing and administration and is therapeutically equivalent to the pioneer drug.

“We’re focused on building a portfolio around the products veterinarians use every day,” added Lauren Landolph. “Clindamycin Hydrochloride Tablets are an important addition to that strategy and reflect our commitment to delivering trusted veterinary treatment options.”

About Felixvet

Founded in 2015 by Dr. Shumeet Banerji, Jon Symonds and Neeraj Agrawal, Felix is focused on developing and commercializing high-quality, bioequivalent generic pharmaceutical products for companion animals. The company’s initial focus is to market and distribute these products throughout North America following approval by the U.S. Food and Drug Administration and Health Canada.

Focused exclusively on animal health, Felixvet has established research, development, manufacturing, and commercial capabilities designed to support the evolving needs of veterinary medicine. The company continues to expand its portfolio of FDA-approved pharmaceuticals, providing veterinarians with trusted treatment options across the therapeutic categories they prescribe every day.

Felixvet aims to be the first truly global generic companion animal pharmaceutical company serving the world’s leading veterinary markets while making high-quality, bioequivalent medicines more accessible to veterinarians, pet owners, and the animals they care for.

Media Contact

Paula Flavin
Project Marketing Manager, US Operations
D: 816-912-2000
E: info@felixvet.com

Kansas City, Mo. — September 22, 2025 — Felixvet Inc. is proud to announce a recent FDA approval for Clindamycin Hydrochloride Tablets, an oral antibiotic approved for use in dogs to treat skin infections, abscesses, dental infections and osteomyelitis caused by susceptible bacterial strains.

“With the approval of Clindamycin Hydrochloride Tablets, we’re expanding access to a trusted treatment option that veterinarians rely on for managing common yet potentially serious infections,” said Vince Palasota, President of North America at Felixvet. “This product reflects our ongoing commitment to quality, affordability and clinical relevance.”

Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis and has demonstrated activity against a broad spectrum of aerobic and anaerobic bacteria, including Staphylococcus aureus, Staphylococcus intermedius, Bacteroides fragilis and Clostridium perfringens. It is especially effective for deep-seated infections, such as those in bone or dental tissues.

The tablets are available in 25 mg, 75 mg and 150 mg strengths and are dosed every 12 hours, with duration of treatment varying based on infection type, typically a few days for acute infections and up to 28 days for osteomyelitis.

“Clindamycin is a proven, versatile therapeutic, and we’re proud to add it to our growing portfolio,” added Palasota. “We look forward to continuing to deliver solutions that meet the daily needs of veterinarians and their patients.”

Felixvet established its North American headquarters in Kansas City, Missouri, in 2023. Felixvet currently holds 20 FDA approvals, with multiple additional products in development and launches planned across a broad range of therapeutic categories.

For more information, contact info@felixvetus.com.

About Felixvet:
Founded in 2015 by Dr. Shumeet Banerji, Jon Symonds and Neeraj Agrawal, Felix is in the business of developing bioequivalent generic pharmaceutical products for companion animals. The company’s initial focus is to market and distribute these products in North American markets upon approval by the U.S. Food and Drug Administration and Health Canada. Felix aims to be the first truly global generic companion animal pharmaceutical player, focusing on the top 10 veterinary markets of the world. It aims to make bioequivalent generics available at affordable prices from cGMP-compliant manufacturing plants.

Media Contact:
Paula Flavin
Project/Marketing Manager
D: 1-816-912-2000
Email: info@felixvetus.com

Category: Clindamycin

Felixvet Expands Companion Animal Portfolio with Clindamycin Hydrochloride Tablets

Felixvet Receives FDA Approval for Clindamycin Hydrochloride Tablets